Clinical Trial Update: Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

An update on a Phase 2 trial of pembrolizumab as first-line treatment for advanced-stage classical Hodgkin lymphoma. The study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Cologne | Conditions: Hodgkin Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING